期刊文献+

ltB-TpN47融合基因原核表达系统的构建

The construction of prokaryotic expression product of ltB-TpN47 fusion gene
下载PDF
导出
摘要 目的分别从梅毒螺旋体(Treponema pallidum,Tp)临床菌株和大肠杆菌DNA中扩增ltB和TpN47基因,构建ltB-TpN47融合基因及其原核表达系统。方法采用PCR分别从上述菌株DNA中扩增TpN47基因和ltB基因片段、构建ltB-TpN47融合基因,T-A克隆后测定核苷酸序列。采用质粒pET32和宿主菌E.coliBL21DE3构建ltB-TpN47融合基因原核表达系统,并用不同浓度的IPTG诱导表达。结果所构建的ltB-TpN47融合基因核苷酸序列与从GeneBank中查询并处理得出的数据基本一致。所构建的表达系统pET32-ltB-TpN47的目的重组蛋白(rltB-TpN47)表达量高达细菌总蛋白的1/3左右。结论本文成功地构建了ltB-TpN47融合基因高效原核表达系统。 Objective To amplify ltB gene and TpN47 gene from DNAs of a clinical strain Treponema pallidum and Eseheriehia eoli strain, respectively, and construct ltB-TpN47 fusion gene and its prokaryotie expression system. Methods TpN47 and ltB genes from DNAs of the bacteria mentioned above were amplified and ltB-TpN47 fusion gene was construeted by PCR. Amplification fragments of the target genes were sequenced after T-A cloning. Plasmid pET32 and E.eoli strain BL21 DE3 were applied to construct expression system of the fusion gene. This prokaryotie expression system was expressed under induce- ment with different dosages of IPTG. Results In comparison with the corresponding se- quences registered in GenBank, the nueleotide and putative amino acid sequences of the constructed ltB-TpN47 gene were nearly same, respectively. Expression output of the target recombinant protein (rltB-TpN47) by the constructed expression system pET32-ltB-TpN47- BL21 DE3 was as high as approximate 1/3 of the total bacterial proteins. Conclusion A prokaryotic expression systems with high efficiency of ltB-TpN47 fusion gene is successfully established in this study.
出处 《实验与检验医学》 CAS 2008年第1期27-29,共3页 Experimental and Laboratory Medicine
关键词 梅毒螺旋体/TpN47基因 大肠杆菌/ltB基因 融合基因 克隆/表达 Treponema pallidum / TpN47 gene Escherichia coli / ltB gene fusiongene Cloning / expression
  • 相关文献

参考文献13

  • 1孙峥嵘,孙皓,鲁润铭,李鲁平,郑志红,李淑琴,张兆山.梅毒螺旋体抗原基因的克隆、表达及其在临床检验中的应用[J].中华微生物学和免疫学杂志,2000,20(2):175-178. 被引量:13
  • 2[2]Strober W,Coffman R.Tolerance and immunity in the intestinal immune system[J].Res ImmunoL 1997,148(8-9):489~599.
  • 3[3]Tochikubo K,Isaka M,Yasuda Y,et al.Recombinant cholera toxinB subunit acts as an adjuvant for the mucosal and systemic responses of miCe to mucosally CO-administered bovine serum albumin[J].Vaccine,1998,16(2~3):150~155.
  • 4[4]Verweij WR,de Haan L,Holtrop M,et al.Mucesal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit:induction of systemic IgG and secretory lgA responses in mice by intranasal immunization with influenza virus surface antigen[j].Vaccine,1998,16(20):2069~2076.
  • 5[5]Yamamoto M,McGboe JR,Hagiwara Y,et al,Genetically manipulated bacterial toxin as a new generation mucosal adjuvant[j].Seand J Immunol,2001,53(3):211~217.
  • 6[6]Haan L,Feil IK,Verweij WR,et al.Mutational analysis of the role of ADP-ribosylation activity and GMI-binding activity in the adjuvant properties of the Escherichia eoli heat-labile enteretoxin to wards intranasally administered keyhole limpet hemoeyanin[J].Eur J Immunol.1998,28(4):1243~1250.
  • 7[7]Saito K Shoji J,lnada N,et al.Immunosuppressive effect of choleratoxin B on allergic conjunctivitis model in guinea pig[J].Jpn J Ophthalmol.2001,45(4):332~338.
  • 8[8]Tamura S,Hatori E,Tsumhara T,et al.Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by in tranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin[J],Vaccine.1997,15(2):225~229.
  • 9[9]Douee G,Fontana M,Pizza M,et al.Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin[J].Infect Immune,1997,65(7):2821~2828.
  • 10[10]Sambrook J,Fritseh EF,Maniatis T.Molecular Cloning,A Laboratory Manual[M].2nd edition.New York:Cold Spring Harbor Laboratory Press.1989,pp1.21~1.52,2.60~2.80,7.3~7.35,9.14~9.22.

二级参考文献2

  • 1金冬雁(译),分子克隆实验指南(第2版),1996年
  • 2卢圣栋,现代分子生物学实验技术,1993年

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部